trending Market Intelligence /marketintelligence/en/news-insights/trending/B4E75Bf7NO_iTHkXaGP0Bw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Celgene waives another cancer drug licensing option from OncoMed

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Celgene waives another cancer drug licensing option from OncoMed

Celgene Corp. will not exercise its option to license cancer drug candidate rosmantuzumab from OncoMed Pharmaceuticals Inc.

OncoMed, in a regulatory filing, said Celgene terminated their collaboration agreement with respect to rosmantuzumab, effective Feb. 12, 2019. The decision comes after rosmantuzumab failed to provide compelling evidence of clinical benefit in an early stage clinical trial in patients with solid tumors.

Celgene recently decided against licensing ovarian cancer drug navicixizumab from Redwood City, Calif.-based OncoMed, similarly due to a lack of clinically proven benefit.

The Summit, N.J.-based biopharmaceutical company still has an option to license another anti-cancer stem cell therapy candidate from OncoMed, called etigilimab.